DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a biopharmaceutical and medical device company focused on infectious disease and dermatology, today announced that it had completed the patient visit phase of its previously announced clinical trial to assess the safety and efficacy of EpiCeram® relative to Elidel® in treating the symptoms associated with eczema such as itch and redness as measured by the EASI scoring system. Elidel is the leading immunosuppressant topical therapy for the short-term treatment of atopic dermatitis. The randomized, double blind study consisted of children between the ages of 2 and 18 years and was conducted at two academic sites. For a four-week period, half of the subjects received treatment with EpiCeram® and the other half received treatment with Elidel®. While the study had a goal of enrolling at least 50 patients, study enrollment was terminated at 36 patients as the rate of enrollment at the two sites did not anticipate timely completion of the full cohort of patients. The study results are currently undergoing statistical analysis and the Company expects to receive the final study report during the second quarter of 2008 at which time it will announce the results.
